Satraplatin
(Synonyms: 沙铂; BMS182751; BMY45594; JM216) 目录号 : GC37593
An orally available antineoplastic platinum(IV) complex
Cas No.:129580-63-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Satraplatin is an orally available antineoplastic platinum(IV) complex.1 It is more hydrophobic than cisplatin or oxaliplatin , which reduces transport-determined acquired resistance.1 Satraplatin also displays less neurotoxicity in rats than cisplatin or tetraplatin.2 Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.3
1.Kelland, L.R., Abel, G., McKeage, M.J., et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drugCancer Res.53(11)2581-2586(1993) 2.McKeage, M.J., Boxall, F.E., Jones, M., et al.Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the ratCancer Res.54(3)629-631(1994) 3.Bhargava, A., and Vaishampayan, U.N.Satraplatin: Leading the new generation of oral platinum agentsExpert. Opin. Investig. Drugs18(11)1787-1797(2009)
Cell experiment: | Cells are harvested, counted and distributed to microtiter plates in 100 μL medium at a density of 1×104 cells/well. Appropriate dilutions of test compounds (Satraplatin, etc.) are added to a total volume of 200 μL/well and plates incubated under tissue culture conditions for four days. Stock solutions of the compounds are prepared in either 70% ethanol or DMSO and diluted more than 100-fold for the assays. Solvent controls are included in all tests. Dose response curves are obtained by assessing cell proliferation at twofold drug dilutions in triplicate and used for calculation of IC50 values. Cell growth is quantified using a modified tetrazolium dye assay (MTT) and by measurement of the reduced formazane dye at 450 nm wavelength (medium control set to 100% proliferation)[1]. |
References: [1]. Fiebiger W, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol. 2011 Jan;13(1):43-9. | |
| Cas No. | 129580-63-8 | SDF | |
| 别名 | 沙铂; BMS182751; BMY45594; JM216 | ||
| Canonical SMILES | [Cl-][Pt+4]([O-]C(C)=O)([O-]C(C)=O)([Cl-])([NH3])[NH2]C1CCCCC1 | ||
| 分子式 | C10H22Cl2N2O4Pt | 分子量 | 500.28 |
| 溶解度 | DMSO: ≥ 33 mg/mL (65.96 mM; DMSO can inactivate Satraplatin's activity) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9989 mL | 9.9944 mL | 19.9888 mL |
| 5 mM | 0.3998 mL | 1.9989 mL | 3.9978 mL |
| 10 mM | 0.1999 mL | 0.9994 mL | 1.9989 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet